Share-based Payment Arrangement, Expense of Virpax Pharmaceuticals, Inc. from 31 Dec 2020 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Virpax Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 31 Dec 2024.
  • Virpax Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2024 was $7,200.
  • Virpax Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2024 was $134,699, a 75% decline year-over-year.
  • Virpax Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $134,699, a 75% decline from 2023.
  • Virpax Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $544,770, a 27% decline from 2022.
  • Virpax Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $745,034, a 24% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Virpax Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $134,699 $7,200 +$16,834 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $117,865 $17,730 -$213,294 -109% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $331,159 $72,510 -$145,747 -67% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $476,906 $72,719 -$67,864 -48% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $544,770 $9,634 -$147,910 -107% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $692,680 $195,564 +$44,847 +30% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $647,833 $218,257 -$26,444 -11% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $674,277 $140,583 -$70,757 -33% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $745,034 $138,276 -$2,874 -2% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $747,908 $150,717 +$8,944 +6.3% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $738,964 $244,701 -$76,726 -24% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $815,690 $211,340 -$158,544 -43% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $974,234 $141,150 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $141,773 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $321,427 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $369,884 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1

Virpax Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $134,699 -$410,071 -75% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $544,770 -$200,264 -27% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $745,034 -$229,200 -24% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $974,234 -$499,408 -34% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $1,473,642 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.